FINWIRES · TerminalLIVE
FINWIRES

TDは、コアインフレ率が目標値に近い水準で推移するとの見通しから、カナダ銀行は来週も金利を据え置くと予想している。

-- TD銀行は月曜日に発表された消費者物価指数(CPI)データを受け、3月のカナダの総合消費者物価指数(CPI)上昇率は前年同月比2.4%増となり、市場予想をわずかに下回ったと発表した。 同行によると、エネルギー価格の上昇が大きな要因であり、エネルギーを除くインフレ率は前年同月比2.2%増と、より「緩やかな」上昇にとどまった。 ガソリン価格は3月に前月比21%上昇し、過去最大の伸びを記録した。 TD銀行は、3月のカナダのインフレ率を押し上げたのは原油価格の上昇だと指摘した。原油価格はここ数日下落しているものの、依然として前年同月比で40%近く高い水準にある。これは、エネルギー価格の高騰が今後もしばらくの間、総合インフレ率を高止まりさせる可能性が高いことを意味する。 同行は、消費者向け炭素税の撤廃によるインフレ抑制効果が前年同月比の計算から除外されるため、4月のインフレ率は大幅に上昇する可能性が高いと述べた。 カナダの経済情勢が全体的に軟調であることを踏まえ、TD銀行はコア物価への影響は「より緩やかなもの」になると予想している。今年のコアインフレ率は、前年比で目標の2%に比較的近い水準で推移すると予想されています。 カナダ銀行は来週の政策発表で、主要政策金利を2.25%に据え置くと広く予想されています。カナダ銀行は、原油価格の高騰がカナダ経済に与える影響に関するカナダ銀行の評価を注視するでしょう。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703